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Objective. To evaluate serum matrix metalloproteinase 3 (MMP-3) levels in 
comparison to C-reactive protein (CRP) in periods with and without progression 
of radiological damage in patients with early rheumatoid arthritis (RA). 
Methods. Thirty-two patients with RA and radiological progression (> 5 points 
according to the Sharp/van der Heijde method) during 6 months followed by a 6 
months period without radiological progression (< 1 point) were selected from a 
prospective follow-up study of early RA patients. Serum MMP-3 levels, CRP, 
erythrocyte sedimentation rate (ESR), disease activity index (DAS), swollen joint 
count (SJC), tender joint count (TJC), Ritchie articular index (RAI) were 
measured monthly and results were transformed into mean values for the 6 
months periods.  
Results. During the period with radiological progression the mean serum MMP-
3 correlated significantly with the mean CRP (r = 0.68, p < 0.001)), ESR (r = 
0.54, p = 0.001) and swollen joint count (r = 0.48, p = 0.006). In the period 
without radiological progression the mean serum MMP-3 only correlated with 
the mean CRP (r = 0.44, p = 0.012). Individual changes - in terms of percentage 
(%) - between the 2 periods showed a decrease in both mean serum MMP-3 and 
CRP in 19 and an increase in 3 patients, in parallel with other markers of disease 
activity in these patients (69% of cases). The individual change (%) in mean 
serum MMP-3 or CRP did not correlate with the difference in radiological 
progression between the 2 periods.  
Conclusions. Serum MMP-3 and CRP are closely related and there seems to be 
no difference between serum MMP-3 and CRP with regard to the monitoring of 
the progression of radiological damage. 
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Rheumatoid arthritis (RA) is characterized by chronic inflammation of synovial 
tissue and in most cases progressive destruction of cartilage and bone 1. The 
matrix metalloproteinases (MMPs) are thought to play a critical role in the degra-
dation of many components of the extracellular matrix in the synovial joint 2,3. 
Matrix metalloproteinase 3 (MMP-3, stromelysin 1) is of interest because this 
proteolytic enzyme is produced abundantly in the inflamed joints and plays a 
prominent role in the pathogenesis of matrix degradation in RA 2-4, even though 
it is not the only key-enzyme 5. MMP-3 is capable of degrading many 
components of the matrix in the synovial joint including proteoglycans, gelatins, 
laminin, fibronectin, and collagen III, IV, IX 2,4,6,7. Moreover MMP-3 is able to 
activate other matrix metalloproteinases such as MMP-1, MMP-7, MMP-8, 
MMP9 and MMP-13 8. The enzyme has been localized in the fibroblast-like 
synoviocytes of rheumatoid synovium 9-11, in RA cartilage 12,13, at sites of 
cartilage erosion 4, in synovial fluid 14-21, and in serum 20,22-26. Systemic MMP-3 
levels are supposed to be a reflection of local synthesis induced by pro-
inflammatory cytokines. As such, serum MMP-3 can be used as a systemic 
marker of local joint inflammation 16,20,24,25,27,28 and/or destruction 26,29,30. In this 
respect serum MMP-3 may reflect joint inflammation and destruction more 
directly compared to C-reactive protein (CRP) which is produced indirectly by 
the liver after cytokine stimulation 31. In addition it has been suggested that the 
pathophysiologic mechanisms of joint inflammation, as reflected by CRP may be 
partially independent of destruction, which is also determined by the prominent 
local cytokine, protease, and inhibitor environment 32-34. This possible 
uncoupling of inflammation and destruction could be one of the explanations for 
the wide inter-individual variation in radiological damage despite comparable 
inflammation as defined by, for example CRP 35. 
We hypothesize that serum MMP-3 is closer related to progression of 
radiological damage in comparison with CRP. Therefore we analyzed mean 
serum MMP-3 levels in a 6 months period with and a consecutive 6 months 
period without progression of radiological damage and evaluated differences 
between serum MMP-3 and CRP. 
 
PATIENTS AND METHODS 
Thirty-two patients with RA and progression of radiological damage (> 5 points 
according to the Sharp/van der Heijde method) during a 6 months period 
followed by a 6 months period with no radiological progression (< 1 point) were 




College of Rheumatology criteria 36 with joint symptoms existing less than one 
year at presentation and who had not previously received DMARDs. These 
patients participated in a prospective follow-up study at the Department of 
Rheumatology at the Groningen University Hospital. According to the protocol 
clinical and laboratory investigations were performed at monthly intervals and 
radiographs of hands and feet were obtained every 6 months of follow-up.  
During follow-up patients were treated with nonsteroidal anti-inflammatory 
drugs  and disease modifying antirheumatic drugs (DMARDs) as indicated 
clinically. Guidelines for the sequence of the different second-line drugs were as 
follows: hydroxychloroquine or sulphasalazine as first choice therapy, followed 
in order by intramuscular gold, D-penicillamine, azathioprine, or methotrexate. 
Low dose corticosteroids could be administered as adjuvant therapy.  
 
Clinical markers of disease activity 
Fifty-two peripheral joints were examined for tenderness and soft tissue swelling. 
The following articular indices were determined: Ritchie articular index (RAI) 37, 
tender joint count (TJC), swollen joint count (SJC) and the disease activity score 
(DAS) according to Van der Heijde with 3 variables: RAI, number of swollen 
joints, and erythrocyte sedimentation rate (ESR) 38. The maximal scores are: RAI 
78, TJC 52, SJC 52 and DAS 10.0. 
 
Laboratory analysis 
Serum MMP-3 levels were determined by a MMP-3 ELISA developed at our 
laboratory 39. In short, 96 well plates were precoated with F(ab)2 fragment of 
goat-antimouse IgG, 1µg/ml (Jackson Immunoresearch Labs, West Grove, PN, 
USA). Next a mouse monoclonal antibody against human MMP-3, clone 10D6 
(R&D Systems, Abingdon, UK) was coated at 0.1 µg/ml. Serum samples were 
analyzed in two-fold serial dilutions in high performance ELISA buffer (CLB, 
Amsterdam, NL) and incubated during 1 hour. After washing bound MMP-3 was 
detected with a polyclonal rabbit-anti-human MMP-3 (AB 810, Chemicon, 
Temecula, CA, USA), followed by horseradish-peroxidase-labelled F(ab)2 
fragment of goat-anti-rabbit IgG (Zymed, San Francisco, CA, USA). Peroxidase 
activity was determined using tetramethylbenzidin as substrate. MMP-3 levels 
were calculated at the linear range of the assay from a standard curve (3-400 
ng/ml) using pro-MMP-3, purified from serum free supernatant of IL-1β 
stimulated rheumatoid arthritis synovial fibroblasts 40. The intra-assay coefficient 
of variation (CV) was 6.8%, the inter-assay CV 8.8%. With an immunoblot we 
demonstrated that both the monoclonal and the polyclonal antibody reacted with 
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active MMP-3, pro-MMP-3, as well as with MMP-3 bound to tissue inhibitor of 
matrix metalloproteinases (TIMPs). Furthermore it was demonstrated that 
rheumatoid factors do not react in this assay and do not interfere with 
measurement of MMP-3 (data not shown). For normal values of serum MMP-3 
the 95 percentile in healthy bloodbank donors (n=80) was used (female < 20 
ng/ml, male < 60 ng/ml) 39. 
CRP was measured by ELISA 41 (lowest limit of detection: 2 mg/l), ESR 
according to Westgren. IgM rheumatoid factor (RF) was measured by 
Dade/Behring BN-2 nephelometer (normal value: < 15 IU/ml).  
 
Radiological analysis 
Radiological damage in hands and feet was assessed by Sharp’s method with 
some modifications as described by Van der Heijde et al 42,43. By this method 
joint space narrowing (JSN) and erosions (ER) are scored separately and 
combined to a total Sharp score (TSS) with a maximum TSS of 448 points. The 
radiographs were scored without knowledge of clinical and laboratory data in 
chronological order per patient by two observers. The inter-observer agreement 
was 0.90 and the intra observer agreements were 0.96 and 0.99 for the two 
observers respectively. Radiological progression was defined as > 5 Sharp points 
and no radiological progression as < 1 Sharp point in a 6 months period. 
 
Statistical analysis 
Monthly determined values of clinical and laboratory variables were transformed 
in a mean value over a 6 months period. Individual changes between the 2 
periods were expressed in terms of percentage. For example: 
 
∆ serum MMP-3 =    
 
Individual mean serum MMP-3 in the non-progressive period 
 
Individual mean serum MMP-3 in the progressive period  
 
 
 Spearman’s rank correlation coefficients were used for assessment of 
correlation, for differences between periods the paired T-test. P values of < 0.05 
were considered significant.  
 
 





Thirty-two patients with RA and radiological progression (> 5 points according 
to Sharp’s method) during a 6 months period followed by a 6 months period 
without radiological progression (< 1 point) were selected from a cohort of early 
RA patients. The median time between the moment of diagnosis RA and such a 
period was 10 months with a range of 0-31 months. The characteristics of these 
32 patients with RA at the beginning of the period with radiological progression 
are summarized in table 1.  
 
TABLE 1. Characteristics of the 32 patients with RA at the beginning of the 6 months period with 
radiological progression. 
Age  (years) 54 (20-78) 
Gender,  female/male (% female) 23/9 (72%) 
Time until begin progressive period ¶   months 10 (0-31) 
IgM RF positive  (%) 28 (88%) 
Tender joint count  7 (1-44) 
Ritchie articular index  6 (1-40) 
Swollen joint count  6 (1-31) 
Disease activity score  2.9 (1.3-5.7) 
CRP  (mg/l) 11 (2-117) 
ESR  (mm/h) 25 (4-97) 
MMP-3  (ng/ml) 54 (5-2370) 









Values are expressed as the median and range. 
¶: Time between the moment of diagnosis of rheumatoid arthritis and the beginning of the period with 
radiological progression. 
†: T0 is the Sharp score at the beginning and T6 the Sharp score at the end of the 6-month period with 
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The individual mean values of serum MMP-3, CRP, ESR and disease activity 

















FIGURE 1. Individual mean values for serum MMP-3 (A), CRP (B), ESR (C), DAS (disease activity 
score (D) in the 6 months period with vs. the consecutive 6 months period without progression of 
radiological damage. Each dot represents 1 patient (n=32). All mean values decreased significantly (p < 





Individual changes - in terms of percentage – of the mean values between the two 
periods (figure 2) showed a decrease in both serum MMP-3 and CRP in 19 and 
an increase in 3 patients, in parallel with other markers of disease activity in the 

















FIGURE 2. Individual changes - in terms of percentage (∆) - of the mean values of serum MMP-3 in 
relation to CRP (A), ESR (B), and DAS (disease activity score (C)) between the 2 periods. Each dot 
represents 1 patient (n=32). Details concerning MMP-3: 
 
Individual mean serum MMP-3 in the non-progressive period 
   Individual mean serum MMP-3 in the progressive period 
 
A decrease in mean serum MMP-3 is represented by a ∆ serum MMP-3 of < 100 %, an increase by a ∆ 
serum MMP-3 of > 100 %. Spearman correlation showed that ∆ serum MMP-3 correlated significantly 
with ∆ ESR (r = 0.47, p < 0.01) and ∆ DAS (r = 0.43, p < 0.01). The correlation between ∆ serum MMP-
3 and ∆ CRP was borderline significant (r = 0.33, p = 0.06). A separate analysis excluding the data of the 
“CRP non-responders” showed a correlation coefficient of 0.40 with a p value of 0.03. 
 
 
∆ serum MMP-3 = X 100 % 
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There was a discrepancy between change in mean serum MMP-3 and CRP in 6 
patients (19% of cases). In 5 of these patients serum MMP-3 levels ranged from 
22-39 ng/ml and in 2 patients CRP levels ranged from 2-8 mg/l. Small changes in 
measured serum MMP-3 levels resulted in great changes, in terms of percentage. 
In the remaining 4 patients (12% of cases) serum MMP-3 decreased but no CRP 
response could be registered because CRP levels were within the normal range (< 
2 mg/l) in both periods. Spearman correlation showed that ∆ serum MMP-3 
correlated significantly with ∆ ESR (r = 0.47, p < 0.01) and ∆ DAS (r = 0.43, p < 
0.01). The correlation between ∆ serum MMP-3 and ∆ CRP was borderline 
significant (r = 0.33, p = 0.06). A separate analysis excluding the data of the 
“CRP non-responders” (n=4) showed a correlation coefficient of 0.40 and p = 
0.03. 
The median change in serum MMP-3 was 61.8% (range: 4-204%), the median 
change in CRP 54.7% (range: 13-228%). 
The individual change - in terms of percentage - in mean serum MMP-3 or CRP 
did not correlated with the difference in radiological progression (figure 3) 
between the 2 periods (∆ serum MMP-3 vs. ∆ Sharp: r = -0.14, p = 0.45 and ∆ 
CRP vs. ∆ Sharp: r = -0.12, p = 0.50).  
 
 
FIGURE 3. Individual changes - in terms of percentage (∆) – of the mean values of serum MMP-3 (A) 
and CRP (B) in relation to the difference in the Sharp score between the 2 periods. Each dot represents 1 
patient (n=32). The individual change (mainly decrease, defined as < 100%) in mean MMP-3 or CRP did 
not correlated with the difference in radiological progression between the two periods (∆ serum MMP-3 






In the period without radiological progression disease activity was moderate-high 
(DAS > 2.4) in 9 patients, low (DAS 1.6 – 2.4) in 16 patients and 7 patients were 
in remission (DAS < 1.6), (figure 1D). Patients with an increase in serum MMP-
3, CRP or ESR in the period without radiological progression (n=3) had DAS 
scores of  > 1.6. 
 
DISCUSSION 
In RA markers of disease activity and destruction are important, not only for 
prognostic but also for therapeutical reasons. Acute phase proteins, such as CRP 
are indirectly produced by the liver after stimulation by cytokines produced at the 
inflammatory site. Serum MMP-3 is locally produced and activated in the 
inflamed joint and systemic levels are supposed to be a direct reflection of local 
synthesis. As such serum MMP-3 could be used as a systemic marker of local 
inflammation and destruction. 
In RA serum MMP-3 is closely correlated to other markers of disease activity 
like swollen joint count, CRP, and ESR 16,20,22,24,25,27-29,34,44,45. Cross-sectional and 
long-term follow-up studies also show correlation between serum MMP-3 and 
radiological detectable damage 16,29. 
 Recent studies suggest that the pathophysiologic mechanisms of joint 
inflammation, as reflected by CRP and destruction may be partially independent 
32-34. Because of the key role of MMP-3 in matrix degradation and the relation 
between serum MMP-3 levels and radiological damage, we evaluated the serum 
MMP-3 levels in periods with and without progression of radiological damage in 
patients with early RA. We hypothesized that serum MMP-3 is closer related to 
progression of radiological damage in comparison with CRP. 
In rheumatoid arthritis a distinction must be made between process variables 
such as CRP and outcome measures like radiological progression. The course of 
the disease is generally monitored by serial measurements of one or more process 
variables. As radiological outcome is essentially the result of what has happened 
during the course of the disease, theoretically the area under the curve of serially 
measured process variables meets the requirements of a proper outcome measure 
46. For equally spaced observations, as is the case in this study, the area under the 
curve is essentially the same as the mean of all measurements 47. Such a 
transformation of data enables the comparison of process variables with outcome 
measures. 
In this select group of RA patients we found, in the first place a close 
correlation between mean serum MMP-3 and CRP in both periods. Secondly, 
evaluation of individual changes - in terms of percentage - between the 2 periods 
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showed a discrepancy between change in mean serum MMP-3 and CRP in only a 
minority of patients, especially in patients with low or close to normal values. In 
the third place, individual changes - in terms of percentage - in mean serum 
MMP-3 or CRP did not correlate to the differences in radiological progression 
between the 2 periods. In this study we did not observe a difference between 
serum MMP-3 and CRP in relation to the progression of radiological damage. Or 
in other words, in this select group of RA patients we could not find arguments 
for an uncoupling of inflammation as reflected by CRP and destruction as 
reflected by serum MMP-3. 
An influence of differences in therapy was considered but could, unfortunately 
not be evaluated due to diversity in used DMARDs in this relative small number 
of RA patients. 
The lack of a difference between serum MMP-3 and CRP in relation to 
progression of radiological damage could have several reasons. In the first place 
patient selection could be of influence. In our attempt to look for differences 
between serum MMP-3 and CRP in relation to progression of radiological 
damage we have chosen a radiological criterium. Patients with radiological 
progression (> 5 points according to Sharp’s method) during 6 months followed 
by a 6 months period with no radiological progression (< 1 point) were selected 
from a large follow-up cohort of RA patients. The cut-off point of > 5 Sharp 
points was inspired by the publications concerning minimal clinical important 
difference and the smallest detectable difference in the Sharp score which scores 
damage in hands and feet 48 With these criteria, even in the non-progressive 
period, 9 patients had a high-moderate disease activity score (see figure 1D) 
probably due to disease activity in other joints. This persistent disease activity 
makes it difficult to evaluate the uncoupling of disease activity assessed by CRP, 
joint counts, DAS and radiological damage scored by X-rays of hands and feet. 
In addition it is of importance to notice that there were some patients with 
radiological progression despite a relatively low disease activity, according to the 
DAS score. This emphasizes the inter-individual difference in the relation 
between parameters of disease activity and radiological damage. 
Secondly it is conceivable that a lag time could play a role 35,49. Radiological 
detectable damage could lag behind disease activity as measured by CRP or 
serum MMP-3. It remains debatable if all the 32 patients were actually in 
“radiological remission”.  
In the third place sample size could be of importance. With the criteria 
mentioned we could select 32 patients out of a cohort of 405 RA patients. This 




are closely related, which implies a relative great sample size. 
Finally, in RA MMP-3 is produced in the inflamed joints as an inactive pro-
enzyme. Upon activation it is able to degrade many components of the matrix. 
Inactivation occurs by inhibitors such as TIMPs (tissue inhibitors of matrix 
metalloproteinases). It is conceivable that an imbalance between production, 
activation and inhibition results in joint destruction (radiological damage). In our 
hypothesis we assume that serum MMP-3, consisting mainly pro-MMP-3, is a 
direct reflection of local pro-MMP-3 production as well as of its local activation 
and subsequent joint destruction. In this respect serum MMP-3 could reflect joint 
destruction more directly compared to CRP which is produced indirectly by the 
liver after cytokine stimulation. The fact that we did not find a difference 
between serum MMP-3 and CRP with regard to radiological progression implies 
that not only production but rather the balance between activation and inhibition 
is of major importance. Unfortunately these mechanisms are difficult to evaluate. 
The optimal biochemical marker for monitoring destruction has still to be 
defined 50. Therefore, although serum MMP-3 remains an interesting marker in 
patients with rheumatoid arthritis, it is not superior to CRP. CRP is still an 
excellent parameter not only for monitoring disease activity but also for 
monitoring progression of radiological detectable damage. 
In conclusion, serum MMP-3 and CRP are closely related and there seems to be 
no difference between serum MMP-3 and CRP with regard to the monitoring of 
the progression of radiological damage. 
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